PubMed Health⌕ Search

Biomedical subjects

R Bliem

Publications and source records attributed to R Bliem.

5 recordsLinked to original sources

Quality control and assurance from the development to the production of biopharmaceuticals.

Consumer and patient safety have become the prerequisites for (bio)pharmaceutical product development, production and marketing. The ability to provide an effective, pure, safe product is the primary factor determining the product's success. However, with an ever-increasing number of national and international regulations, 'quality assurance' has acquired a threatening ring for many project managers. Many think that ensuring and improving quality is expensive, but regulations aid public acceptance. Good manufacturing practice can be developed into a business asset and need not be seen as merely a regulatory hurdle.

Drug Design↗

A desktop image processing system for computer-assisted orthopedic surgery (DISOS).

Within the framework of our research activities in orthopedic surgery a PC-based imageprocessing system for the processing of x-ray computer-tomographic data has been developed. The system is used as a work platform for the investigations concerning interaction modalities, strategies and techniques for an efficient planning and execution of surgical interventions in orthopedic surgery by means of individual templates. The method of individual templates has been presented in /1,2/ and will not be subject of this paper.

Computer Peripherals↗

Antibody production in packed bed reactors using serum-free and protein-free medium.

The present work demonstrates the utility of packed bed reactors for the production of monoclonal antibody. We present data from a continuous process run for the production of over 100 grams of antibody, using serum-free medium. An additional pilot run also demonstrates the potential for continued antibody production under protein-free conditions, using a standard basal medium.

Animals↗

Performance characteristics of mammalian cell culture process operating continuously with protein-free medium.

In this communication we briefly describe a continuous industrial process for the production of Tissue Plasminogen Activator (tPA), operating with a standard, basal medium (DME/F12). Process data of two culture runs has been chosen to present a performance profile over a production period of more than 3 mo. Developmental aspects of glucose utilization (as a process parameter) are briefly discussed.

Culture Media↗